Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.

Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D.

Sci Adv. 2019 Feb 20;5(2):eaav2437. doi: 10.1126/sciadv.aav2437. eCollection 2019 Feb.

2.

Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Zuiverloon TCM, Theodorescu D.

Eur Urol. 2019 Apr;75(4):694. doi: 10.1016/j.eururo.2018.12.019. Epub 2019 Jan 17. No abstract available.

PMID:
30661731
3.

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D.

Bladder Cancer. 2018 Oct 3;4(Suppl 1):S1-S43. doi: 10.3233/BLC-189037. No abstract available.

4.

Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice.

Sottnik JL, Mallaredy V, Chauca-Diaz A, Ritterson Lew C, Owens C, Dancik GM, Pagliarani S, Lucchiari S, Moggio M, Ripolone M, Comi GP, Frierson HF, Clouthier D, Theodorescu D.

Carcinogenesis. 2019 Mar 12;40(1):194-201. doi: 10.1093/carcin/bgy139.

PMID:
30403777
5.

Metastatic cells are preferentially vulnerable to lysosomal inhibition.

Morgan MJ, Fitzwalter BE, Owens CR, Powers RK, Sottnik JL, Gamez G, Costello JC, Theodorescu D, Thorburn A.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8479-E8488. doi: 10.1073/pnas.1706526115. Epub 2018 Aug 20.

6.

A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition.

Goodspeed A, Jean A, Theodorescu D, Costello JC.

Bladder Cancer. 2018 Jul 30;4(3):269-282. doi: 10.3233/BLC-170161.

7.

RalA controls glucose homeostasis by regulating glucose uptake in brown fat.

Skorobogatko Y, Dragan M, Cordon C, Reilly SM, Hung CW, Xia W, Zhao P, Wallace M, Lackey DE, Chen XW, Osborn O, Bogner-Strauss JG, Theodorescu D, Metallo CM, Olefsky JM, Saltiel AR.

Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7819-7824. doi: 10.1073/pnas.1801050115. Epub 2018 Jun 18.

8.

Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.

Zuiverloon TCM, de Jong FC, Costello JC, Theodorescu D.

Bladder Cancer. 2018 Apr 26;4(2):169-183. doi: 10.3233/BLC-180167.

9.

Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth.

Richmond CS, Oldenburg D, Dancik G, Meier DR, Weinhaus B, Theodorescu D, Guin S.

Oncotarget. 2018 Mar 30;9(24):16718-16730. doi: 10.18632/oncotarget.24676. eCollection 2018 Mar 30.

10.

Two methods of prediction signatures.

Jones RT, Theodorescu D.

Nat Rev Urol. 2018 Jun;15(6):340-342. doi: 10.1038/s41585-018-0004-2. No abstract available.

PMID:
29581570
11.

A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.

Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Sze CC, Wang L, Zhao Z, Crawford SE, Hu D, Licht JD, Collings CK, Bartom E, Theodorescu D, Shilatifard A, Meeks JJ.

Oncogene. 2018 Apr;37(14):1911-1925. doi: 10.1038/s41388-017-0099-6. Epub 2018 Jan 25.

12.

Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.

Zuiverloon TCM, de Jong FC, Theodorescu D.

Oncology (Williston Park). 2017 Dec 15;31(12):855-62. Review.

13.

RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.

Yan C, Theodorescu D.

Pharmacol Rev. 2018 Jan;70(1):1-11. doi: 10.1124/pr.117.014415. Review.

14.

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Felsenstein KM, Theodorescu D.

Nat Rev Urol. 2018 Feb;15(2):92-111. doi: 10.1038/nrurol.2017.179. Epub 2017 Nov 14. Review.

PMID:
29133939
15.

Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.

Duex JE, Swain KE, Dancik GM, Paucek RD, Owens C, Churchill MEA, Theodorescu D.

Mol Cancer Res. 2018 Jan;16(1):69-77. doi: 10.1158/1541-7786.MCR-17-0260. Epub 2017 Oct 2.

16.

New Sister Journal Kidney Cancer.

Lerner SP, Theodorescu D.

Bladder Cancer. 2017 Jul 27;3(3):143. doi: 10.3233/BLC-179021. No abstract available.

17.

Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.

Zuiverloon TC, Theodorescu D.

Pharmacogenomics. 2017 Aug;18(12):1167-1178. doi: 10.2217/pgs-2017-0055. Epub 2017 Jul 26. Review.

PMID:
28745580
18.

Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.

Duex JE, Owens C, Chauca-Diaz A, Dancik GM, Vanderlinden LA, Ghosh D, Leivo MZ, Hansel DE, Theodorescu D.

Cancer Res. 2017 Sep 15;77(18):4858-4867. doi: 10.1158/0008-5472.CAN-17-0367. Epub 2017 Jul 3.

19.

Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach.

Ngo AT, Thierheimer ML, Babur Ö, Rocheleau AD, Huang T, Pang J, Rigg RA, Mitrugno A, Theodorescu D, Burchard J, Nan X, Demir E, McCarty OJ, Aslan JE.

Am J Physiol Cell Physiol. 2017 Apr 1;312(4):C527-C536. doi: 10.1152/ajpcell.00274.2016. Epub 2017 Feb 1.

20.

CD44: A metastasis driver and therapeutic target.

Sottnik JL, Theodorescu D.

Oncoscience. 2016 Dec 30;3(11-12):320-321. doi: 10.18632/oncoscience.335. eCollection 2016. No abstract available.

21.

The Role of Transcription Factor YY1 in the Biology of Cancer.

Agarwal N, Theodorescu D.

Crit Rev Oncog. 2017;22(1-2):13-21. doi: 10.1615/CritRevOncog.2017021071. Review.

PMID:
29604933
22.

Synthesis of novel Ral inhibitors: An in vitro and in vivo study.

Yan C, Theodorescu D, Miller B, Kumar A, Kumar V, Ross D, Wempe MF.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5815-5818. doi: 10.1016/j.bmcl.2016.10.021. Epub 2016 Oct 12.

23.

Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX.

BMC Genomics. 2016 Oct 25;17(1):829. No abstract available.

24.

CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL).

Oldenburg D, Ru Y, Weinhaus B, Cash S, Theodorescu D, Guin S.

BMC Cancer. 2016 Sep 5;16:713. doi: 10.1186/s12885-016-2756-5.

25.

An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA.

Cancer Cell. 2016 Sep 12;30(3):432-443. doi: 10.1016/j.ccell.2016.08.002. Epub 2016 Sep 1.

26.

GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.

Agarwal N, Dancik GM, Goodspeed A, Costello JC, Owens C, Duex JE, Theodorescu D.

Cancer Res. 2016 Sep 1;76(17):5175-85. doi: 10.1158/0008-5472.CAN-16-1099. Epub 2016 Jun 16.

27.

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Nickerson ML, Witte N, Im KM, Turan S, Owens C, Misner K, Tsang SX, Cai Z, Wu S, Dean M, Costello JC, Theodorescu D.

Oncogene. 2017 Jan 5;36(1):35-46. doi: 10.1038/onc.2016.172. Epub 2016 Jun 6.

28.

High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing.

Duberow DP, Brait M, Hoque MO, Theodorescu D, Sidransky D, Dasgupta S, Mathies RA.

J Mol Med (Berl). 2016 Sep;94(9):1015-24. doi: 10.1007/s00109-016-1407-2. Epub 2016 Mar 31.

PMID:
27030170
29.

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.

Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP.

Clin Cancer Res. 2016 Aug 15;22(16):4077-86. doi: 10.1158/1078-0432.CCR-15-2715. Epub 2016 Mar 29.

30.

Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.

Gustafson DL, Fowles JS, Brown KC, Theodorescu D.

Assay Drug Dev Technol. 2015 Dec;13(10):623-7. doi: 10.1089/adt.2015.29012.dlgdrrr.

31.

Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies.

Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX.

BMC Genomics. 2015 Nov 30;16(1):1019. doi: 10.1186/s12864-015-2227-4. No abstract available.

32.

Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.

Jones RT, Felsenstein KM, Theodorescu D.

Urol Clin North Am. 2016 Feb;43(1):77-86. doi: 10.1016/j.ucl.2015.08.007. Epub 2015 Oct 31. Review.

33.

Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.

Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR.

Genes Dev. 2015 Nov 1;29(21):2219-24. doi: 10.1101/gad.269498.115. Epub 2015 Oct 29.

34.

Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.

Guin S, Ru Y, Agarwal N, Lew CR, Owens C, Comi GP, Theodorescu D.

Clin Cancer Res. 2016 Mar 1;22(5):1274-83. doi: 10.1158/1078-0432.CCR-15-1706. Epub 2015 Oct 21.

35.

A whole-genome RNAi screen uncovers a novel role for human potassium channels in cell killing by the parasite Entamoeba histolytica.

Marie C, Verkerke HP, Theodorescu D, Petri WA.

Sci Rep. 2015 Sep 8;5:13613. doi: 10.1038/srep13613.

36.

Drugging the Ral GTPase.

Yan C, Jones DN, Theodorescu D.

Small GTPases. 2015;6(3):157-9. doi: 10.1080/21541248.2015.1018403.

37.

Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.

Hensel J, Duex JE, Owens C, Dancik GM, Edwards MG, Frierson HF, Theodorescu D.

Mol Cancer Res. 2015 Sep;13(9):1306-15. doi: 10.1158/1541-7786.MCR-15-0130. Epub 2015 Jun 15.

38.

Targeting glycogen metabolism in bladder cancer.

Ritterson Lew C, Guin S, Theodorescu D.

Nat Rev Urol. 2015 Jul;12(7):383-91. doi: 10.1038/nrurol.2015.111. Epub 2015 May 26. Review.

39.

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX.

BMC Genomics. 2015 May 22;16:403. doi: 10.1186/s12864-015-1450-3. Erratum in: BMC Genomics. 2015;16(1):1019. BMC Genomics. 2016 Oct 25;17 (1):829.

40.

New and promising strategies in the management of bladder cancer.

Apolo AB, Vogelzang NJ, Theodorescu D.

Am Soc Clin Oncol Educ Book. 2015:105-12. doi: 10.14694/EdBook_AM.2015.35.105. Review.

41.

The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer.

Dancik GM, Theodorescu D.

Bladder Cancer. 2015 Apr 30;1(1):45-63. doi: 10.3233/BLC-150012.

42.

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.

Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR.

Science. 2015 Feb 27;347(6225):1006-10. doi: 10.1126/science.1260200. Epub 2015 Feb 5.

43.

Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation.

Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince T, Durante MA, Guo W, Mills G, Theodorescu D, Slingerland J.

Oncogene. 2015 Oct;34(43):5447-59. doi: 10.1038/onc.2014.473. Epub 2015 Feb 16.

44.

A rho GDP dissociation inhibitor produced by apoptotic T-cells inhibits growth of Mycobacterium tuberculosis.

Venkatasubramanian S, Dhiman R, Paidipally P, Cheekatla SS, Tripathi D, Welch E, Tvinnereim AR, Jones B, Theodorescu D, Barnes PF, Vankayalapati R.

PLoS Pathog. 2015 Feb 6;11(2):e1004617. doi: 10.1371/journal.ppat.1004617. eCollection 2015 Feb.

45.

One step closer to targeting RAS.

Yan C, Theodorescu D.

Cell Cycle. 2015;14(3):287-8. doi: 10.1080/15384101.2015.1006534. No abstract available.

46.

The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.

Guin S, Theodorescu D.

Acta Pharmacol Sin. 2015 Mar;36(3):291-7. doi: 10.1038/aps.2014.129. Epub 2015 Jan 5. Review.

47.

RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer.

Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, Brautigan DL, Theodorescu D.

Mol Cancer Res. 2015 Mar;13(3):483-92. doi: 10.1158/1541-7786.MCR-14-0420. Epub 2014 Dec 16.

48.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Review.

49.

Looking forward, looking back-10 years in urology.

Albersen M, Cartwright R, Choyke P, Goldenberg SL, Goldman H, Lawrentschuk N, Linehan WM, Murphy D, Nagler H, Scardino P, Shortliffe L, Stenzl A, Theodorescu D.

Nat Rev Urol. 2014 Nov;11(11):649-55. doi: 10.1038/nrurol.2014.263. Epub 2014 Oct 28. Review.

PMID:
25348169
50.

Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties.

Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, Bui KH, Fristrup N, Christensen EI, Nordentoft I, Morth JP, Jensen JB, Pedersen JS, Beck M, Theodorescu D, Borre M, Howard KA, Dyrskjøt L, Ørntoft TF.

Cancer Res. 2014 Oct 15;74(20):5758-71. doi: 10.1158/0008-5472.CAN-13-3512. Epub 2014 Sep 26.

Supplemental Content

Loading ...
Support Center